A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease
2022-06-29
عنوان الدراسة
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease
داعم الدراسة
Abbvie Biopharmaceuticals GmbH / KSU Liver Disease Research Center
دواء الدراسة
ombitasvir \ paritaprevir \ ritonavir
رقم بروتوكول الدراسة
Version 1.3.1
حالة الدراسة
Ongoing
موقع الدراسة
NGHA-J
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。